

CATEGORY	STUDIES	RESPONSIBILITY
Acceptability, Testing/Preliminary Harm Reduction Testing	<ul style="list-style-type: none"> <li>• Literature Review</li> <li>• Smoke Chemistry</li> <li>• Genotoxicity</li> <li>• Cytotoxicity</li> <li>• Sub-chronic inhalation of smoke</li> </ul>	Tobacco Company
Specialized Hard Reduction Testing	<ul style="list-style-type: none"> <li>• Carcinogenicity</li> <li>• Cardiovascular</li> <li>• Non-neoplastic respiratory disease</li> <li>• Reproduction</li> </ul>	Tobacco Company
Human Exposure Assessment	<ul style="list-style-type: none"> <li>• Short-term "clinical"</li> <li>• Assessment in adopters</li> </ul>	Tobacco Company
Short-Term Health Endpoints in Humans	<ul style="list-style-type: none"> <li>• Not yet identified</li> </ul>	Tobacco Company in conjunction with appropriate regulatory agency
Epidemiology	<ul style="list-style-type: none"> <li>• Specific studies not yet defined</li> </ul>	Appropriate regulatory agency in conjunction with tobacco companies
Post-market	<p>Surveillance</p> <ul style="list-style-type: none"> <li>• Post market studies including periodic reports</li> <li>• Adverse event reporting by stakeholders</li> <li>• Medical literature</li> <li>• Morbidity mortality data</li> </ul>	Tobacco Company in conjunction with appropriate regulatory agency and other stakeholders